What happened with TOVX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Theriva Biologics is a clinical-stage biotechnology company focused on viruses designed to infect and destroy cancer cells and stimulate an immune response against tumors. Its business centers on VCN-01, an engineered virus intended for intravenous delivery. It is designed to break down part of the tissue surrounding tumor cells so the virus, other treatments and immune cells can reach them more readily.
The company has no approved product and has never earned product-sale revenue. Its limited income includes an upfront payment from Rasayana Therapeutics for exclusive worldwide rights to products including SYN-020. Rasayana pays for development and commercialization; Theriva can receive further payments as development and sales milestones are met, plus royalties on sales and a share of sublicensing income. Those payments depend on Rasayana's progress and commercial results.
Theriva has historically funded operations mainly by selling securities. Advancing VCN-01 requires more capital, successful clinical trials and regulatory approval before it can be sold. The company lacks committed financing and funding to complete registrational trials, while U.S. securities rules restrict its ability to raise money through securities sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Theriva’s results hinge chiefly on VCN-01 clinical progress and financing, while Rasayana Therapeutics controls the SYN-020 development and commercialization behind Theriva’s potential milestone payments and royalties.
Grifols matters to Theriva chiefly as a cash obligation: Theriva owes the plasma-medicine maker acquisition-related milestone payments, not payments for supplying its cancer treatments. The $5 million already earned but deferred pending discussions with Grifols would, if paid, significantly drain Theriva’s cash and impair its ability to fund operations.
TransCode Therapeutics competes with Theriva in developing cancer treatments that kill tumors and stimulate an immune response, though TransCode has no approved products or revenue from any source through December 31, 2025. Progress in its UIO-524 oncolytic immunotherapy is the news most relevant to Theriva’s tumor-killing virus pipeline, led by VCN-01.
Grifois, S.A. earningsGRFS
Grifols’ report will show the plasma-medicine maker’s financial condition, helping readers gauge the pressure of Theriva’s deferred $5 million obligation without indicating whether or when it will be paid.
Look at Grifols’ operating cash flow and liquidity alongside Theriva’s limited cash and its disclosure that paying the earned $5 million would significantly deplete funds. Stronger finances could make payment more feasible, but payment would squeeze Theriva’s operating resources; weaker finances could leave timing less clear. Grifols’ report cannot confirm whether or when Theriva will pay.
Theriva Biologics, Inc. earningsThis company
Theriva Biologics has no product sales and is focusing its resources on the cancer candidate VCN-01; this report will show whether cash use and research spending leave room to keep developing it.
Read the cash balance alongside cash used in operations, then check whether research spending still supports VCN-01. Slower cash use with continued VCN-01 work would show that limited funds can still support the lead program; faster depletion or higher spending would mean further trials depend more on new financing or a partner.
